版本:
中国

BRIEF-Redhill Biopharma reports enrollment of last patient in bekinda phase II study

April 24 Redhill Biopharma Ltd:

* Redhill Biopharma Ltd- Redhill Biopharma announces enrollment of last patient in bekinda phase II study for IBS-D

* Redhill Biopharma Ltd- top-line results are expected in Q3 of 2017

* Redhill Biopharma Ltd- top-line results from a phase III study with bekinda 24 mg for acute gastroenteritis and gastritis are expected in Q2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐